scout
|Videos|January 9, 2018

Dr. Domchek on Promising Biomarkers in Breast Cancer

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses promising biomarkers in breast cancer.

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses promising biomarkers in breast cancer.

Biomarkers such as BRCA1/2 are currently used to determine treatment for patients with breast cancer, explains Domcheck.

Domcheck adds that if a patient is microsatellite instability-high (MSI-H), then that patient can receive pembrolizumab (Keytruda) regardless of tumor site.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME